Skip to content
mapperlab
← Dashboard
Stock

MED

Medifast, Inc.
Latest close $124 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
4
27 funds tracked
Ever held
9
Current + past
New this quarter
0
Exited this quarter
0

Marquee-fund ownership over time

May 15, 2018Aug 14, 2019Aug 9, 2024Nov 14, 2025
Now
4

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies$20$12-36%
Two Sigma Investments$19$12-33%
D.E. Shaw$19$12-33%
AQR Capital Management$19$12-33%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Millennium Management→ $11-39%
Citadel Advisors→ $13-30%
Bridgewater Associates→ $19-91%
Maverick Capital 2× in & out→ $205+45%
Coatue Management 2× in & out→ $85-28%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at MEDIFAST INC. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
7
Filings · last 90d
10
Total on file
457
Recent SEC buffer
Most recent
May 28, 2026

30d / 90d windows measured from May 28, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 457 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · Medifast, Inc.

Annual figures sourced directly from Medifast, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$385.79M
FY2025-36% YoY
Net income
-$18.67M
FY2025-500%+ YoY
EPS (diluted)
$-1.70
FY2025-500%+ YoY
Free cash flow(?)
$1.25M
FY2025-93% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for MEDIFAST INC — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Citadel AdvisorsQ3 2024Q3 2025$19$13-30%
Two Sigma InvestmentsQ3 2024open$19$12-33%
D.E. ShawQ3 2024open$19$12-33%
AQR Capital ManagementQ3 2024open$19$12-33%
Millennium ManagementQ3 2024Q4 2025$19$11-39%
Renaissance TechnologiesQ3 2024open$20$12-36%
Bridgewater AssociatesQ3 2021Q3 2024$210$19-91%
Maverick CapitalQ3 2020Q4 2021$142$205+45%
Coatue ManagementQ2 2019Q3 2019$117$85-28%
Coatue ManagementQ3 2018Q1 2019$175$108-38%
Maverick CapitalQ2 2018Q3 2018$105$175+67%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.